From: Bisphosphonates and risk of atrial fibrillation: a meta-analysis
Study, Year, Country | Subjects | Mean age (year) | Mean duration (year) | Type of bisphosphonate | AF definition | Total AF events (n) | Variables matched and/or controlled | Quality assessment score§ |
---|---|---|---|---|---|---|---|---|
Heckbert and colleagues [7], 2008, USA | 1,685 women in a commercial health care system database | 73 | 20 | Alendronate | ICD-9 codes verified by medical records +/- EKG | 719 | Age, HTN, calendar year, osteoporosis, and any cardiovascular disease | 4/2/3 |
Sorensen and colleagues [19], 2008, Denmark | 81,640 women in the National Registry of Patients | >75 | Not reported | Alendronate Etidronate | ICD-8 and 10 codes | 13586 | Age, county, cardiovascular disease, renal failure, DM, HRT, fracture, cancer, alcoholism, pulmonary disease, anti-thyroid drugs, osteoporosis, steroid use, etc | 3/2/3 |
Grosso and colleagues* [16], 2009, UK | 2,195 women with AF in the UK General Practice Research Database | 82 | 13 | Alendronate Risedronate | Diagnosis codes and Read codes | 2195 | Age+ | 3/2/3 |
Levesque and colleagues [18], 2009, Canada | 63,843 adults (BIS users and raloxifene users) in the Quebec health database | 75 | 4 | Alendronate Etidronatea Risedronatea | Not reported | 2149 | Age, cohort entry year, follow-up, CAD, HTN, and use of HRT | N/A |